Qube Research & Technologies LTD Cytom X Therapeutics, Inc. Transaction History
Qube Research & Technologies LTD
- $62.3 Billion
- Q2 2024
A detailed history of Qube Research & Technologies LTD transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 54,608 shares of CTMX stock, worth $63,891. This represents 0.0% of its overall portfolio holdings.
Number of Shares
54,608
Previous 133,199
59.0%
Holding current value
$63,891
Previous $290,000
77.24%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding CTMX
# of Institutions
76Shares Held
50.2MCall Options Held
22.3KPut Options Held
22.9K-
Tang Capital Management LLC San Diego, CA7.79MShares$9.12 Million1.16% of portfolio
-
Janus Henderson Group PLC London, X06.3MShares$7.37 Million0.0% of portfolio
-
Bvf Inc San Francisco, CA5.23MShares$6.12 Million0.2% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.89MShares$5.72 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3MShares$3.51 Million0.01% of portfolio
About CytomX Therapeutics, Inc.
- Ticker CTMX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,950,200
- Market Cap $77.2M
- Description
- CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...